EvolusEOLS +3.41%71 EBITDA Margin % is -5.13% as of Mar. 2026. GuruFocus rates EOLS with a GF Score™ of 71/100 and a GF Value™ of $13.59 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Evolus ranks worse than 79.27% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Evolus's EBITDA for the
three
months ended in Mar. 2026 was $-3.8 Mil. Evolus's Revenue for the
three
months ended in Mar. 2026 was $73.1 Mil. Therefore, Evolus's EBITDA margin for the quarter that ended in Mar. 2026 was -5.13%.
Evolus (NAS:EOLS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Evolus EBITDA Margin % Related Terms
Evolus EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Evolus's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOLS vs EBS, ELTP, AQST: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Evolus's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus (EOLS) has a EBITDA Margin % of -5.13% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evolus and its competitors. According to the industry distribution chart, Evolus ranks #757 out of 955 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is Evolus' EBITDA Margin % too high?
Evolus' current EBITDA Margin % is -5.13%. Based on the distribution chart, Evolus ranks #757 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evolus has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' EBITDA Margin % compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #757 out of 955 companies for EBITDA Margin %. This places Evolus in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evolus and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current EBITDA Margin % is -5.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.59, compared to a current price of $6.97 — trading 48.7% below its estimated fair value. The current EBITDA Margin % is -5.13%. Evolus' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Evolus (EOLS), the current EBITDA Margin % is -5.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $6.97 is trading 48.7% below its estimated GF Value™ of $13.59.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
EBITDA Margin %: -5.13%
GF Value™: $13.59 vs. price of $6.97 (48.7% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
71GF Score
Get the complete analysis for EOLS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
